<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="endocrinology" lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher">JOHS</journal-id>
      <journal-id journal-id-type="nlm-ta">Journ of Health Scien</journal-id>
      <journal-title-group>
        <journal-title>Journal of HealthCare Sciences</journal-title>
        <abbrev-journal-title abbrev-type="pubmed">Journ of Health Scien</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2231-2196</issn>
      <issn pub-type="opub">0975-5241</issn>
      <publisher>
        <publisher-name>Radiance Research Academy</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">286</article-id>
      <article-id pub-id-type="doi">http://dx.doi.org/10.52533/JOHS.2024.40902</article-id>
      <article-id pub-id-type="doi-url"/>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Endocrinology</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Tirzepatide Safety and Efficacy in Managing Type 2 Diabetes and Obesity: A Systemic Review and Meta-Analysis&#13;
</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Soqati</surname>
            <given-names>Abrar Abdullateef</given-names>
          </name>
        </contrib>
      </contrib-group>
      <pub-date pub-type="ppub">
        <day>4</day>
        <month>09</month>
        <year>2024</year>
      </pub-date>
      <volume>4</volume>
      <issue>9</issue>
      <fpage>338</fpage>
      <lpage>356</lpage>
      <permissions>
        <copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement>
        <copyright-year>2009</copyright-year>
        <license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that has shown potential in managing type 2 diabetes mellitus (T2DM) and obesity. This systematic review and meta-analysis aim to evaluate the efficacy and safety of tirzepatide by consolidating evidence from relevant studies. A systematic search of electronic databases such as PubMed, Scopus, Cochrane Library, Web of Science, and ScienceDirect was done to identify randomized controlled trials (RCTs) and clinical trials evaluating the efficacy and safety of tirzepatide in adult participants with T2DM and/or obesity. The inclusion criteria required studies to report results on glycemic control (HbA1c levels), weight loss, and adverse events. Two researchers extracted data separately. The Cochrane Risk of Bias tool was used to assess methodological quality and potential bias. Statistical analyses were conducted using R software 4.2.2. Heterogeneity among studies was assessed using the Cochrane Q p-value and I² statistic, with publication bias evaluated through funnel plots and Egger__ampersandsign#39;s regression test. The present study included 6 articles from 2018 to 2023. The quality assessment revealed some methodological concerns, but most studies demonstrated a low risk of bias in key areas. Tirzepatide led to a significant reduction in HbA1c levels (MD: -2.5078; 95% CI: [-3.3945, -1.6210]), fasting blood glucose (FBG) (MD: -62.78; 95% CI: [-67.9269, -57.6337]), waist circumference (MD: -8.60; 95% CI: [-15.5491, -1.6410]), and body weight (MD: -10.7852; 95% CI: [-14.8264, -6.7439]) compared to placebo. A non-significant trend towards fewer serious adverse events (RR: 0.7423; 95% CI: [0.4771, 1.1547]) and reduced mortality risk (RR: 0.2727; 95% CI: [0.0286, 2.2766]) was observed. Tirzepatide appears promising in managing type 2 diabetes and obesity, significantly enhancing glycemic control, reducing body weight, and decreasing waist circumference, all while maintaining a favorable safety profile. Further research is warranted to address methodological concerns and confirm long-term benefits and risks.&#13;
</p>
      </abstract>
      <kwd-group>
        <kwd>Tirzepatide</kwd>
        <kwd> type 2 diabetes mellitus</kwd>
        <kwd> obesity</kwd>
        <kwd> management</kwd>
        <kwd> glycemic control</kwd>
        <kwd> weight loss</kwd>
      </kwd-group>
    </article-meta>
  </front>
</article>